SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses. / Christensen, Dennis; Polacek, Charlotta; Sheward, Daniel J.; Hanke, Leo; McInerney, Gerald; Murrell, Ben; Hartmann, Katrine Top; Jensen, Henrik Elvang; Zimmermann, Julie; Jungersen, Gregers; Illigen, Kristin Engelhart; Isling, Louise Krag; Fernandez-Antunez, Carlota; Ramirez, Santseharay; Bukh, Jens; Pedersen, Gabriel Kristian.

In: Frontiers in Immunology, Vol. 14, 941281, 2023.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Christensen, D, Polacek, C, Sheward, DJ, Hanke, L, McInerney, G, Murrell, B, Hartmann, KT, Jensen, HE, Zimmermann, J, Jungersen, G, Illigen, KE, Isling, LK, Fernandez-Antunez, C, Ramirez, S, Bukh, J & Pedersen, GK 2023, 'SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses', Frontiers in Immunology, vol. 14, 941281. https://doi.org/10.3389/fimmu.2023.941281

APA

Christensen, D., Polacek, C., Sheward, D. J., Hanke, L., McInerney, G., Murrell, B., Hartmann, K. T., Jensen, H. E., Zimmermann, J., Jungersen, G., Illigen, K. E., Isling, L. K., Fernandez-Antunez, C., Ramirez, S., Bukh, J., & Pedersen, G. K. (2023). SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses. Frontiers in Immunology, 14, [941281]. https://doi.org/10.3389/fimmu.2023.941281

Vancouver

Christensen D, Polacek C, Sheward DJ, Hanke L, McInerney G, Murrell B et al. SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses. Frontiers in Immunology. 2023;14. 941281. https://doi.org/10.3389/fimmu.2023.941281

Author

Christensen, Dennis ; Polacek, Charlotta ; Sheward, Daniel J. ; Hanke, Leo ; McInerney, Gerald ; Murrell, Ben ; Hartmann, Katrine Top ; Jensen, Henrik Elvang ; Zimmermann, Julie ; Jungersen, Gregers ; Illigen, Kristin Engelhart ; Isling, Louise Krag ; Fernandez-Antunez, Carlota ; Ramirez, Santseharay ; Bukh, Jens ; Pedersen, Gabriel Kristian. / SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses. In: Frontiers in Immunology. 2023 ; Vol. 14.

Bibtex

@article{b13bb1de303d41948d0e3ed601fe623f,
title = "SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses",
abstract = "SARS-CoV-2 continues to pose a threat to human health as new variants emerge and thus a diverse vaccine pipeline is needed. We evaluated SARS-CoV-2 HexaPro spike protein formulated in Alhydrogel{\textregistered} (aluminium oxyhydroxide) in Syrian hamsters, using an accelerated two dose regimen (given 10 days apart) and a standard regimen (two doses given 21 days apart). Both regimens elicited spike- and RBD-specific IgG antibody responses of similar magnitude, but in vitro virus neutralization was low or undetectable. Despite this, the accelerated two dose regimen offered reduction in viral load and protected against lung pathology upon challenge with homologous SARS-CoV-2 virus (Wuhan-Hu-1). This highlights that vaccine-induced protection against SARS-CoV-2 disease can be obtained despite low neutralizing antibody levels and suggests that accelerated vaccine schedules may be used to confer rapid protection against SARS-CoV-2 disease.",
keywords = "accelerated schedule, alum, neutralizing antibodies, SARS-CoV-2, subunit vaccine",
author = "Dennis Christensen and Charlotta Polacek and Sheward, {Daniel J.} and Leo Hanke and Gerald McInerney and Ben Murrell and Hartmann, {Katrine Top} and Jensen, {Henrik Elvang} and Julie Zimmermann and Gregers Jungersen and Illigen, {Kristin Engelhart} and Isling, {Louise Krag} and Carlota Fernandez-Antunez and Santseharay Ramirez and Jens Bukh and Pedersen, {Gabriel Kristian}",
note = "Publisher Copyright: Copyright {\textcopyright} 2023 Christensen, Polacek, Sheward, Hanke, McInerney, Murrell, Hartmann, Jensen, Zimmermann, Jungersen, Illigen, Isling, Fernandez-Antunez, Ramirez, Bukh and Pedersen.",
year = "2023",
doi = "10.3389/fimmu.2023.941281",
language = "English",
volume = "14",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - SARS-CoV-2 spike HexaPro formulated in aluminium hydroxide and administered in an accelerated vaccination schedule partially protects Syrian Hamsters against viral challenge despite low neutralizing antibody responses

AU - Christensen, Dennis

AU - Polacek, Charlotta

AU - Sheward, Daniel J.

AU - Hanke, Leo

AU - McInerney, Gerald

AU - Murrell, Ben

AU - Hartmann, Katrine Top

AU - Jensen, Henrik Elvang

AU - Zimmermann, Julie

AU - Jungersen, Gregers

AU - Illigen, Kristin Engelhart

AU - Isling, Louise Krag

AU - Fernandez-Antunez, Carlota

AU - Ramirez, Santseharay

AU - Bukh, Jens

AU - Pedersen, Gabriel Kristian

N1 - Publisher Copyright: Copyright © 2023 Christensen, Polacek, Sheward, Hanke, McInerney, Murrell, Hartmann, Jensen, Zimmermann, Jungersen, Illigen, Isling, Fernandez-Antunez, Ramirez, Bukh and Pedersen.

PY - 2023

Y1 - 2023

N2 - SARS-CoV-2 continues to pose a threat to human health as new variants emerge and thus a diverse vaccine pipeline is needed. We evaluated SARS-CoV-2 HexaPro spike protein formulated in Alhydrogel® (aluminium oxyhydroxide) in Syrian hamsters, using an accelerated two dose regimen (given 10 days apart) and a standard regimen (two doses given 21 days apart). Both regimens elicited spike- and RBD-specific IgG antibody responses of similar magnitude, but in vitro virus neutralization was low or undetectable. Despite this, the accelerated two dose regimen offered reduction in viral load and protected against lung pathology upon challenge with homologous SARS-CoV-2 virus (Wuhan-Hu-1). This highlights that vaccine-induced protection against SARS-CoV-2 disease can be obtained despite low neutralizing antibody levels and suggests that accelerated vaccine schedules may be used to confer rapid protection against SARS-CoV-2 disease.

AB - SARS-CoV-2 continues to pose a threat to human health as new variants emerge and thus a diverse vaccine pipeline is needed. We evaluated SARS-CoV-2 HexaPro spike protein formulated in Alhydrogel® (aluminium oxyhydroxide) in Syrian hamsters, using an accelerated two dose regimen (given 10 days apart) and a standard regimen (two doses given 21 days apart). Both regimens elicited spike- and RBD-specific IgG antibody responses of similar magnitude, but in vitro virus neutralization was low or undetectable. Despite this, the accelerated two dose regimen offered reduction in viral load and protected against lung pathology upon challenge with homologous SARS-CoV-2 virus (Wuhan-Hu-1). This highlights that vaccine-induced protection against SARS-CoV-2 disease can be obtained despite low neutralizing antibody levels and suggests that accelerated vaccine schedules may be used to confer rapid protection against SARS-CoV-2 disease.

KW - accelerated schedule

KW - alum

KW - neutralizing antibodies

KW - SARS-CoV-2

KW - subunit vaccine

U2 - 10.3389/fimmu.2023.941281

DO - 10.3389/fimmu.2023.941281

M3 - Journal article

C2 - 36756130

AN - SCOPUS:85147446052

VL - 14

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 941281

ER -

ID: 337599975